Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: A new opioid analgesic formulation and beyond

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 999-1001

  Ruan, Xiulu ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Abuse; deterrent; Embeda; opioid

Indexed keywords

6 BETA NATREXOL; ANALGESIC AGENT; ARSENAL; DRUG METABOLITE; MORPHINE; MORPHINE SULFATE PLUS NALTREXONE; NALTREXONE; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MISUSE; DRUG SAFETY; HUMAN; OPIATE ADDICTION; PAIN; PRESCRIPTION; REVIEW; SUSTAINED RELEASE FORMULATION;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; DRUG COMBINATIONS; HUMANS; MORPHINE; NALTREXONE; OPIOID-RELATED DISORDERS; PAIN;

EID: 79953852244     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.571208     Document Type: Review

References (9)

1. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000;12:1710-14 (Pubitemid 30196211)
2. American Academy of Pain Medicine, American Pain Society. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and American Pain Society. Clin J Pain 1997; 13: 6-8.
3. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39
4. National Center on Addiction and Substance Abuse (NCASA). Under the counter: the diversion and abuse of controlled prescription drugs in the United Sates. NCASA, New York; 2005
5. Substance Abuse Mental Health Services Administration (SAMSHA). National survey on drug use & health national results. SAMSHA, Services DoHaHm, Rockville, MD; 2007. Contract no.: DHHS Publication no. SMA 07-4293
6. FDA Consumer Health Information. Combating misuse and abuse of prescription drugs. FDA Consumer Health Information/US Food and Drug Administration, July 2010. Available from: http:/www.fda.gov/downloads/ ForConsumers/ConsumerUpdates/UCM220434.pdf [Last accessed 8 October 2010]
7. Jang DH, Rohe JC, Hoffman RS, Nelson LS. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med 2010;55:303-4
8. Ruan X, Chen T, Gudin J, et al. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag 2010;6:300-3
9. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006;3:489-97